Spinal Changes Of A Newly Isolated Neuropeptide Endomorphin-2 Concomitant With Vincristine-Induced Allodynia

Yang Yang,Yong-Gang Zhang,Guo-An Lin,He-Qiu Xie,Hai-Tao Pan,Ben-Qing Huang,Ji-Dong Liu,Hui Liu,Nan Zhang,Li Li,Jian-Hua Chen

DOI: https://doi.org/10.1371/journal.pone.0089583

IF: 3.7

2014-01-01

PLoS ONE

Abstract:Chemotherapy-induced neuropathic pain (CNP) is the major dose-limiting factor in cancer chemotherapy. However, the neural mechanisms underlying CNP remain unclear. There is increasing evidence implicating the involvement of spinal endomorphin-2 (EM2) in neuropathic pain. In this study, we used a vincristine-evoked rat CNP model displaying mechanical allodynia and central sensitization, and observed a significant decrease in the expression of spinal EM2 in CNP. Also, while intrathecal administration of exogenous EM2 attenuated allodynia and central sensitization, the mu-opioid receptor antagonist beta-funaltrexamine facilitated these events. We found that the reduction in spinal EM2 was mediated by increased activity of dipeptidylpeptidase IV, possibly as a consequence of chemotherapy-induced oxidative stress. Taken together, our findings suggest that a decrease in spinal EM2 expression causes the loss of endogenous analgesia and leads to enhanced pain sensation in CNP.